We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ultrasound and Self-Healing Hydrogels Noninvasively Deliver Targeted Chemotherapy

By HospiMedica International staff writers
Posted on 08 Jul 2014
Modern drug-delivery systems used to administer chemotherapy to cancer patients typically release a constant dose of the drug over time. More...
But a new study challenges this gradual approach and offers a unique way to locally deliver the drugs “on demand.”

The study’s findings were reported online ahead of print June 24, 2014, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS). Led by David J. Mooney, PhD, a core faculty member at Harvard University’s Wyss Institute for Biologically Inspired Engineering and a professor of bioengineering at the Harvard School of Engineering and Applied Sciences (SEAS; Cambridge, MA, USA), the scientists packed a biocompatible hydrogel with a chemotherapy drug and used ultrasound to trigger the gel to release the agent. Similar to many other injectable gels that have been employed for drug delivery for decades, this one slowly releases a low level of the agent by diffusion over time. To temporarily increase doses of drug, scientists had earlier applied ultrasound--but that strategy was a one-shot job as the ultrasound was used to destroy those gels. However, this gel was different.

The investigators used ultrasound to temporarily disrupt the gel such that it released short, high-dose bursts of the drug--similar to opening up a floodgate. But when they stopped the ultrasound, the hydrogels self-healed. By closing back up, they were ready to go for the next “on demand” drug burst—providing an innovative way to administer drugs with a far greater level of control than possible before. Furthermore, the investigators also demonstrated in lab cultures and in mice with breast cancer tumors that the pulsed, ultrasound-triggered hydrogel approach to drug delivery was more effective at blocking the growth of tumor cells than conventional, sustained-release drug therapy.

“Our approach counters the whole idea of sustained drug release, and offers a double whammy,” said Prof. Mooney. “We have shown that we can use the hydrogels repeatedly and turn the drug pulses on and off at will, and that the drug bursts in concert with the baseline low-level drug delivery seems to be particularly effective in killing cancer cells.”

The advance holds potential implications for improved cancer treatment and other therapies requiring drugs to be delivered at the right place and the right time—from post-surgery pain medications to protein-based drugs that require daily injections. It requires an initial injection of the hydrogel, but the approach could be a much less traumatic, minimally invasive and more effective method of drug delivery overall, according to Prof. Mooney said.

“We want to give clinicians the ability to deliver drugs as locally as possible combined with the flexibility to temporally control the dose,” said co-lead author Nathanial Huebsch, PhD, who was a Harvard SEAS graduate student in the Harvard-Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) division of health sciences and technology at the time of the research. For example, many cancer patients require a regular dose of pain killers, but unpredictable pain attacks require them to take much larger doses over a short time.

Key to the success of the project was devising a hydrogel that self-heals is choosing the right kind of hydrogel with the right kind of drug—and applying the right intensity of ultrasound. “We were able to trigger our system with a level of ultrasound that was much lower than high-intensity focused ultrasound that is used clinically to heat and destroy tumors,” said co-lead author Cathal Kearney, PhD, who was a postdoctoral fellow at SEAS at the time of the study. “The careful selection of materials and properties make it a reversible process,” Dr. Kearney said.

The scientists performed most of their research for this study with a gel composed of alginate, a natural polysaccharide from algae that is held together with calcium ions. In a series of laboratory tests they found that with the correct level of ultrasound waves, the bonds break up and enable the gel to release its drug payload, but as long as the gel in in the presence of more calcium, the bonds reform and the gels self-heal.

Once the researchers figured out that the gel would self-heal, they evaluated a drug that they believed it would hold well—in this instance, a chemotherapy drug called mitoxantrone, which is frequently used to treat breast cancer. In fact, the ultrasound triggered the gel to release the blue-colored drug, as indicated by the newly blue color of the surrounding medium. Only one ultrasound dose was effective, and the gel reformed after it was disrupted, making multiple cycles possible.

Next, they tested the treatment on mice that had human breast cancer tumors implanted in their bodies. They injected the drug-laden gel close to the tumors, and over the course of six months the mice that received a low-level sustained release of the drug with a daily concentrated pulse of ultrasound (only 2.5 minutes) fared significantly better than mice treated the same but without ultrasound. In contrast to the other groups, the tumors in the ultrasound-treated mice did not grow substantially and, moreover, the mice survived for an additional 80 days.

“These results demonstrate how applying novel engineering approaches and programmable nanomaterials can create entirely new solutions to critical medical problems,” said Wyss Institute rounding director Don Ingber, MD, PhD, who is also a professor of vascular biology at Harvard Medical School and Boston Children’s Hospital (Boston, MA, USA), and professor of bioengineering at Harvard SEAS. “Dave’s work shows that these new responsive hydrogels that remodel reversibly when exposed to ultrasound energy at the nanoscale not only provide a new way to administer drugs on demand, they also produce better responses to therapy even in a disease as difficult to treat as cancer.”

This development to use simple ultrasound pulses and readily available hydrogels in a new way comes after Prof. Mooney’s work using low-power lasers to stimulate stem cells to regenerate the material that comprises teeth. The scientists also demonstrated that the gel can release other kinds of cargo as well, including proteins, which lays the foundation for potentially using these hydrogels for tissue regeneration, and condensed plasmid DNA, suggesting their potential use in gene therapy.

The scientists next plan to examine these other potential applications, as well as the possibility of releasing two different drugs independently from the same hydrogel, according to Prof. Mooney.

Related Links:

Harvard University School of Engineering and Applied Sciences



Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gas Analyzer
GE SAM
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Artificial intelligence (AI) standalone performance and reader performance with versus without AI assistance. (A) Receiver operating characteristics (ROC) curve for AI standalone performance in the US dataset (AUC 0.899, 95% CI 0.858 to 0.939). (B) ROC curve for AI standalone performance in the Korean dataset (AUC 0.963, 95% CI 0.946 to 0.975). (C) Pooled reader ROC without (AUC 0.718) versus with (AUC 0.852) AI assistance in the Korean dataset; P<0.001. AUC, area under the receiver operating characteristics curve. (Leonard Sunwoo et al., Journal of NeuroInterventional Surgery (2026). DOI: 10.1136/jnis-2026-025339)

AI Improves Non-Contrast CT Interpretation for Time-Sensitive Stroke Assessment

Acute ischemic stroke occurs when a blood vessel in the brain becomes blocked, requiring rapid diagnosis to enable timely reperfusion therapy. Emergency departments often use computed tomography angiography... Read more

Critical Care

view channel
Image: Anatomically guided sonography for trauma assessment includes a mixed reality headset (e.g., top left). Example views show virtual augmentation overlays for anatomy registration and ultrasound probe guidance on a test surrogate. The anatomical display is customized based on the organ or region being targeted with the ultrasound probe. (Robert S. Armiger, Anna E. Knight, Catherine M. Carneal, et al. Journal of Medical Imaging (2026). DOI: 10.1117/1.jmi.13.4.045001)

Anatomical Guidance System Improves Trauma Ultrasound Acquisition by Novice Users

Focused assessment with sonography for trauma (FAST) helps clinicians detect free fluid and signs of internal bleeding in injured patients, but obtaining reliable images can be difficult for inexperienced operators.... Read more

Surgical Techniques

view channel
Image: MIT researchers have developed a handheld device capable of gently collecting living cells from specific locations to test for ovarian and many other types of cancer. (Photo courtesy of Kripa Varanasi, et al)

Handheld Device Improves Targeted Cell Collection for Early Ovarian Cancer Assessment

High-grade serous ovarian cancer is the most common form of ovarian cancer, and many cases are thought to originate in the fallopian tubes. Because precursor lesions can be microscopic, they are difficult... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.